About Altheos
Altheos is a company based in San Francisco (United States) founded in 2010. It operates as a B2B. Altheos has raised $32.5 million across 2 funding rounds from investors including Canaan, Bay City Capital and Novo Holdings. Altheos operates in a competitive market with competitors including Nephron Pharmaceuticals, Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm and Suanfarma, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$32.5 M (USD)
in 2 rounds
-
Latest Funding Round
$12.5 M (USD), Series A
Feb 09, 2012
-
Investors
Canaan
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Altheos
Altheos has successfully raised a total of $32.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12.5 million completed in February 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Altheos
Altheos has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Canaan, Bay City Capital and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life-sciences sectors are managed.
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for Altheos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Altheos
Investment portfolio details for Altheos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Altheos
Detailed financials for Altheos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Altheos Comparisons
Peer comparison for Altheos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Altheos
Altheos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nephron Pharmaceuticals, Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm and Suanfarma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sterile pharmaceutical products are manufactured and contract services are provided.
|
|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
|
| Locked | Locked | Locked |
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
|
| Locked | Locked | Locked |
Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions
|
Detailed competitors of Altheos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Altheos
Complete news archive for Altheos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Altheos
Altheos was founded in 2010.
Altheos is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Altheos is a funded company, having raised a total of $32.5M across 2 funding rounds to date.
Altheos, established in 2010 and currently in Dissolved stage, focuses on providing healthcare solutions, producing pharmaceutical products, research and development, and drug manufacturing. Focuses on RD and manufacturing of drugs for various therapeutic areas. Adapting to market demands with innovation and client-focused strategies.
Altheos's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.
Altheos has 5 investors. Key investors include Canaan, Bay City Capital, Novo Holdings, Life Science Angels, and Atheneos Ventures.